IRLAB Therapeutics

IRLAB Therapeutics

Pre-clinical
Gothenburg, SwedenFounded 2010irlab.se

ISP – The proprietary technology platform IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

Founded
2010
Focus
Small Molecules

About

ISP – The proprietary technology platform IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

Funding History

3

Total raised: $60M

IPO$30MUndisclosedJun 5, 2020
Series B$20MFlerie InvestJun 15, 2018
Series A$10MFlerie InvestJun 15, 2016

Company Info

TypePrivate
Founded2010
LocationGothenburg, Sweden
StagePre-clinical

Contact

SIMILAR COMPANIES
Basic Genomics
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
2A Pharma
Phase 1 · Stockholm
Abliva
Abliva
Pre-clinical · Lund
Affibody
Affibody
Phase 1 · Solna
Alligator Bioscience
Alligator Bioscience
Phase 1 · Lund
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile